Theravance Biopharma's total assets for Q2 2025 were $426.04M, an increase of 24.00% from the previous quarter. TBPH total liabilities were $201.19M for the fiscal quarter, a 13.28% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.